Search
Belinostat
go.drugbank.com/drugs/DB05015ApprovedInvestigationalThe safety and efficacy of belinostat is currently being evaluated for use in combination with traditional front-line therapies for the treatment of PTCL. … It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget.
Synonyms: (2E)-N-HYDROXY-3-(3-(PHENYLSULFAMOYL)PHENYL)PROP-2-ENAMIDE, N-Hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamideLindane
go.drugbank.com/drugs/DB00431ApprovedWithdrawnIn Canada, Lindane is not recommmended as a first-line therapy due to reports of resistance, neurotoxicity, and bone marrow suppression, but has been approved by the FDA as a second-line therapy for topical … treatment of pediculosis capitis (head lice), pediculosis pubis (pubic lice), or scabies in patients greater than two years of age who cannot tolerate or have failed first-line treatment.
Categories: Compounds used in a research, industrial, or household settingAmbroxol
go.drugbank.com/drugs/DB06742ApprovedInvestigationalSurfactants acts as an anti-glue factor by reducing the adhesion of mucus to the bronchial wall, in improving its transport and in providing protection against infection and irritating agents. … role in the body’s natural defence mechanisms.
Synonyms: Cyclohexanol, 4-((2-amino-3,5-dibromobenzyl)amino)- (E)-, N-(2-Amino-3,4-dibromociclohexil)-trans-4-aminociclohexanolMixtures: LARITOL EX, TUKOL EXTilmicosin
go.drugbank.com/drugs/DB11471InvestigationalVet approvedIt is used in veterinary medicine for the treatment of bovine respiratory disease and ovine respiratory disease associated with _Mannheimia haemolytica_.
Products: EM-MICOFEED 10% GranulesDeferasirox
go.drugbank.com/drugs/DB01609ApprovedInvestigationalDeferasirox is an iron chelator and the first oral medication FDA approved for chronic iron overload in patients receiving long term blood transfusions.
Categories: Compounds used in a research, industrial, or household settingProducts: DEFERASIROX EGAmenorrhea, Postpartum
go.drugbank.com/conditions/DBCOND0110846Imatinib
go.drugbank.com/drugs/DB00619ApprovedInvestigationalBrian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and typically occurred in the first four weeks of therapy". … [L42220] Imatinib was approved on February 1st ,2001 by the FDA and November 7th, 2001 by the EMA; however, its European approval has been withdrawn in October 2023.[A263036,L49746,L49751]
Products: IMATINIB EGLoratadine
go.drugbank.com/drugs/DB00455ApprovedInvestigational[A176435] A lack of sedative and CNS adverse effects make loratadine, along with other second generation antihistamines, preferable over their 1st generation counterparts in many clinical situations.
Mixtures: LARITOL EX, LARITOL EXProducts: LORATADINA EGHydralazine
go.drugbank.com/drugs/DB01275ApprovedInvestigational[A186820,L8782,L8785] Hydralazine is no longer a first line therapy for these indications since the development of newer antihypertensive medications. … [A186841] Hydralazine is a hydrazine derivative vasodilator used alone or as adjunct therapy in the treatment of hypertension and only as adjunct therapy in the treatment of heart failure.
Mixtures: Ser-Ap-Es, Ser-AP-ES TabCategories: Arteriolar Smooth Muscle, Agents Acting OnGlimepiride
go.drugbank.com/drugs/DB00222ApprovedInvestigational[A177703] Glimepiride was approved by the Food and Drug Administration (FDA) in the United States in 1995 for the treatment of T2DM. … SUs due to minimal effects on ischemic preconditioning of cardiac myocytes.
Categories: Drugs Used in DiabetesProducts: GLIMEPIRIDE EG